Koyfin Home > Directory > Health Care > Acceleron Pharma > EBITDA / Interest Expenses

Acceleron Pharma EBITDA / Interest Expenses Chart (XLRN)

Acceleron Pharma annual/quarterly EBITDA / Interest Expenses from 2012 to 2014. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Acceleron Pharma EBITDA / Interest Expenses for the quarter ending March 03, 2014 was $-13m a 252.87% decrease of -33m year over year
  • Acceleron Pharma EBITDA / Interest Expenses for the last 12 months ending December 12, 2014 was $-54m a 94.61% decrease of -51m year over year
  • Acceleron Pharma Annual EBITDA / Interest Expenses for 2014 was $-54m a 107.03% decrease of -57m from 2013
  • Acceleron Pharma Annual EBITDA / Interest Expenses for 2013 was $4m a 579.94% increase of 22m from 2012
  • Acceleron Pharma Annual EBITDA / Interest Expenses for 2012 was $-18m a 226.78% decrease of -41m from 2011
Other Ratios Metrics:
  • Acceleron Pharma Total Debt / Capital for the quarter ending December 12, 2013 was $23m a -6,253.89% decrease of -1,413m year over year
  • Acceleron Pharma Other Liabilities for the quarter ending December 12, 2018 was $4m a 14.46% increase of 1m year over year
  • Acceleron Pharma Total Debt / Equity for the quarter ending December 12, 2013 was $29m
View Chart On Koyfin

Quarterly XLRN EBITDA / Interest Expenses Data

03/2014$-13m
12/2013$-7m
09/2013$-14m
06/2013$20m
03/2013$8m
12/2012$-16m
09/2012$-13m
06/2012$-24m
03/2012$-28m

Annual XLRN EBITDA / Interest Expenses Data

2014$-54m
2013$4m
2012$-18m
2011$23m